About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT03988335

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Lead sponsor: Aristea Therapeutics, Inc.•17 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Aristea Therapeutics, Inc.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•At least a 6-month history of PPP as defined by the presence of pustules on palms and/or soles, but without evidence of infection on palms and soles
•Moderate or severe PPP, as defined by Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) ≥8 and Palmoplantar Pustulosis Physician Global Assessment (PPPGA) ≥3 at Day -1, and a minimum of 8 fresh pustules at screening (fresh pustule count on both right/left palms and soles) and 20 fresh pustules at Day -1 (fresh pustule count on both right/left palms and soles)
•Males and females must be willing to use birth control as indicated

Exclusion Criteria

•Moderate to severe psoriasis, as defined by plaque psoriasis covering ≥10% of total Body Surface Area (BSA) at Day -1
•Subject is known to have an immune deficiency or is immunocompromised
•Positive test for hepatitis, human immunodeficiency virus (HIV) or tuberculosis
•Use of topical therapies for PPP within 2 weeks of Day -1 and/or systemic therapies for PPP within 4 weeks

Related studies

RECRUITINGPhase 2

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201 · Palmoplantar Pustulosis

Not Yet RecruitingPhase 3

A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

NCT07530367 · Palmoplantar Pustulosis (PPP)

TERMINATEDPhase 4

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

NCT05710185 · Palmoplantar Pustulosis

A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

NCT04459507 · Palmoplantar Pustulosis

TERMINATEDPhase 2

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT05194839 · Palmoplantar Pustulosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 5, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment35

Start dateFeb 2019

Last updatedApr 5, 2022

Condition

Palmoplantar Pustulosis

Locations shown

Kirk Barber Research

Calgary, Alberta

Alberta DermaSurgery Centre

Edmonton, Alberta

CARe Clinic (Central Alberta Research Clinic)

Red Deer, Alberta

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 5, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions